The present invention relates to a novel bacteriophage CJ25 (KCCM11463P) and a composition comprising the same as an active ingredient. In addition, the present invention relates to a method for preventing and/or treating infectious diseases caused by avian pathogenic Escherichia coli (APEC) of birds by using the bacteriophage CJ25 (KCCM11463P) or the composition.

A method of inhibiting the function of myostatin is provided.

An antisense oligonucleotide of 15-30 bases or a salt or a solvate thereof, wherein the antisense oligonucleotide has a nucleotide sequence complementary to a target sequence in exon 3 of the myostatin gene and is capable of allowing the expression of a splicing variant of myostatin. A pharmaceutical drug, a food, a feed, an agent for promoting myocyte proliferation and/or hypertrophy, an agent for increasing muscle mass and/or suppressing muscle weakness, an agent for switching the splicing of the myostatin gene from production of myostatin to production of a splicing variant thereof, an agent for decreasing myostatin signaling, and an anticancer agent, each of which comprises the above antisense oligonucleotide or a salt or a solvate thereof.

A method of inhibiting the function of myostatin is provided.

An antisense oligonucleotide of 15-30 bases or a salt or a solvate thereof, wherein the antisense oligonucleotide has a nucleotide sequence complementary to a target sequence in exon 3 of the myostatin gene and is capable of allowing the expression of a splicing variant of myostatin. A pharmaceutical drug, a food, a feed, an agent for promoting myocyte proliferation and/or hypertrophy, an agent for increasing muscle mass and/or suppressing muscle weakness, an agent for switching the splicing of the myostatin gene from production of myostatin to production of a splicing variant thereof, an agent for decreasing myostatin signaling, and an anticancer agent, each of which comprises the above antisense oligonucleotide or a salt or a solvate thereof.

The present invention relates to a novel method, expression vectors, and host cells for producing nicotinic acid riboside by regulating the pathways that lead to the production of nicotinic acid riboside.

The present invention relates to a new cocktail of bacteriophages with specific lytic activity against Salmonella enteritidis, Salmonella typhimurium and Salmonella paratyphi B., for reducing, eliminating and/or preventing them in farm animals and animals from the poultry sector, such as poultry, hens and breeding hens, in addition to eggs. It may be administered as an additive in the feed, in water or by spray. Moreover, the cocktail may be used as a disinfectant in work areas of farms and abattoirs, and in processed foods, without affecting the organoleptic properties of the product.

Provided herein are small-molecule compounds and combinations thereof that enhance the synthesis of animal endogenous genus host defense peptides, which display potent antimicrobial and immunomodulatory activities. They thus represent alternatives to antibiotics for disease control and prevention for use in animals and humans. Examples of the small molecule compounds include histone deacetylase inhibitors, mono- and disaccharide sugars, cyclic adenosine monophosphate (cAMP) signaling agonists, and cyclooxygenase -2 (COX-2) inhibitors. Synergistic combinations include short-chain fatty acids, their chemical analogs or histone deacetylase inhibitors with other fatty acids, sugars, cAMP signaling agonists, and/or COX-2 inhibitors.

Provided herein are small-molecule compounds and combinations thereof that enhance the synthesis of animal endogenous genus host defense peptides, which display potent antimicrobial and immunomodulatory activities. They thus represent alternatives to antibiotics for disease control and prevention for use in animals and humans. Examples of the small molecule compounds include histone deacetylase inhibitors, mono- and disaccharide sugars, cyclic adenosine monophosphate (cAMP) signaling agonists, and cyclooxygenase -2 (COX-2) inhibitors. Synergistic combinations include short-chain fatty acids, their chemical analogs or histone deacetylase inhibitors with other fatty acids, sugars, cAMP signaling agonists, and/or COX-2 inhibitors.

A flavor composition comprising at least one transmembrane compound and/or at least one nucleotide derivative that modulates, increases and/or enhances the activity of an umami receptor is provided that can be used to enhance the umami taste and/or palatability of food products. In certain, non-limiting embodiments, the flavor composition comprises at least one nucleotide derivative and/or at least one transmembrane compound, optionally at least one nucleotide, optionally at least one first amino acid, optionally at least one second amino acid.

A flavor composition comprising at least one transmembrane compound and/or at least one nucleotide derivative that modulates, increases and/or enhances the activity of an umami receptor is provided that can be used to enhance the umami taste and/or palatability of food products. In certain, non-limiting embodiments, the flavor composition comprises at least one nucleotide derivative and/or at least one transmembrane compound, optionally at least one nucleotide, optionally at least one first amino acid, optionally at least one second amino acid.

The present invention relates to the method for production of a composition comprising at least 15% nucleotides, preferably at least 18% nucleotides, more preferably at least 22% nucleotides and at least 40% amino acids and peptides, and to a composition comprising at least 15% nucleotides, preferably at least 18% nucleotides, more preferably at least 22% nucleotides and at least 40% amino acids and peptides obtainable according to the said method. The method of the present invention involves obtaining the biomass by cultivating at least one microorganism strain(s) characterized by a growth rate in the process of at least 0.85 h-1. The composition of the present invention is particularly useful in the production of animal feed, pet food, food products, fermentation medium or supplement, nutraceuticals, pharmaceuticals, diagnostics, RNA or DNA, or flavour enhancers.